首页> 美国卫生研究院文献>Springer Open Choice >Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

【2h】

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

机译：放线菌素D的临床药代动力学的特征以及ABCB1药代遗传学变异对儿童癌症放线菌素D的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and ObjectiveDespite its important role in cancer treatment, there is currently very limited available information concerning the clinical pharmacology of actinomycin D (Act D). The study was designed to characterise Act D pharmacokinetics and investigate the impact of pharmacogenetic variation on Act D disposition in children with cancer.

机译：背景和目的尽管放线菌素D在癌症治疗中起着重要作用，但目前关于放线菌素D（Act D）的临床药理学的可用信息非常有限。该研究旨在表征Act D药代动力学，并研究药物遗传学变异对癌症儿童Act D处置的影响。

著录项

期刊名称 Springer Open Choice
作者
Christopher R. Hill; Michael Cole; Julie Errington; Ghada Malik; Alan V. Boddy; Gareth J. Veal;
展开▼
作者单位

展开▼
年(卷),期 -1(53),8
年度 -1
页码 741–751
总页数 11
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer [J] . Hill Christopher R., Cole Michael, Errington Julie, Clinical pharmacokinetics . 2014,第8期

机译：放线菌素D的临床药代动力学的表征以及ABCB1药代遗传学变异对儿童癌症放线菌素D的影响
2. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo [J] . Biochemical Pharmacology . 2013,第1期

机译：表征ABCB1，ABCC1，ABCC2和ABCG2在放线菌素D体内外的转运和药代动力学中的作用
3. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer [J] . Walsh Christopher, Bonner Jennifer J., Johnson Trevor N., British Journal of Clinical Pharmacology . 2016,第5期

机译：癌症儿童放线菌素D的基于生理的药代动力学模型的建立
4. U-Net Segmentation Achieve Clinically of HT29 Colon-Cancer Cell to Analyze Variations Morphology in Mitotic Defects and Micro Nuclei [C] . Adiratna Ciptaningrum, I Ketut Eddy Purnama, Reza Fuad Rachmadi International Conference on Computer Engineering, Network, and Intelligent Multimedia . 2020

机译：U-Net分割在临床上实现HT29结肠癌细胞，以分析有丝分裂缺陷和微核的变异形态
5. Integration of preclinical and clinical data with pharmacokinetic modeling and simulations to characterize the disposition of orally-active antiparasitic prodrugs and metabolites: Prediction of the dose-exposure relationship in humans. [D] . Yan, Zhixia. 2011

机译：临床前和临床数据与药代动力学建模和模拟的集成，以表征口服活性抗寄生虫前药和代谢物的分布：预测人类的剂量-暴露关系。
6. Characterisation of the roles of ABCB1 ABCC1 ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo [O] . Christopher R. Hill, David Jamieson, Huw D. Thomas, -1

机译：表征ABCB1ABCC1ABCC2和ABCG2在放线菌素D体内外的转运和药代动力学中的作用
7. Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer [O] . 2014

机译：放线菌素D的临床药代动力学的特征以及ABCB1药代遗传学变异对儿童癌症放线菌素D的影响

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

摘要

著录项

相似文献

相关主题

期刊订阅